These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 27093898)

  • 1. First report of icatibant treatment in a pregnant patient with hereditary angioedema.
    Farkas H; Kőhalmi KV; Veszeli N; Tóth F; Varga L
    J Obstet Gynaecol Res; 2016 Aug; 42(8):1026-8. PubMed ID: 27093898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Hereditary Angioedema Attacks with Icatibant and Recombinant C1 Inhibitor During Pregnancy.
    Hakl R; Kuklínek P; Krčmová I; Králíčková P; Freiberger T; Janků P; Vlková M; Litzman J
    J Clin Immunol; 2018 Oct; 38(7):810-815. PubMed ID: 30280305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icatibant as acute treatment for hereditary angioedema in adults.
    Farkas H
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):779-88. PubMed ID: 27123689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
    Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
    Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H; Reshef A; Aberer W; Caballero T; McCarthy L; Hao J; Nothaft W; Schranz J; Bernstein JA; Li HH
    J Allergy Clin Immunol Pract; 2017; 5(6):1671-1678.e2. PubMed ID: 28601641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
    Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bradykinin B2 receptor antagonist off label use in short-term prophylaxis in hereditary angioedema.
    Angeletti C; Angeletti PM; Mastrobuono F; Pilotti L; Ciccozzi A; Guetti C
    Int J Immunopathol Pharmacol; 2014; 27(4):653-9. PubMed ID: 25572747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.
    Federici C; Perego F; Borsoi L; Crosta V; Zanichelli A; Gidaro A; Tarricone R; Cicardi M
    BMJ Open; 2018 Jul; 8(7):e022291. PubMed ID: 30061443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Icatibant, an inhibitor of bradykinin receptor 2, for hereditary angioedema attacks: prospective experimental single-cohort study.
    Campos RA; Valle SO; França AT; Cordeiro E; Serpa FS; Mello YF; Malheiros T; Toledo E; Mansour E; Fusaro G; Grumach AS
    Sao Paulo Med J; 2014; 132(5):261-5. PubMed ID: 25054967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR; Farkas H; Moldovan D; Toubi E; Baptista J; Craig T; Riedl M
    Int Arch Allergy Immunol; 2015; 168(1):44-55. PubMed ID: 26556097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evidence based therapeutic approach to hereditary and acquired angioedema.
    Bork K
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment options for hereditary angioedema due to C1 inhibitor deficiency.
    Wu MA; Zanichelli A; Mansi M; Cicardi M
    Expert Opin Pharmacother; 2016; 17(1):27-40. PubMed ID: 26512744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?
    Šimac DV; Štimac T; Novak S
    Curr Allergy Asthma Rep; 2022 Oct; 22(10):135-140. PubMed ID: 36044174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.
    Fox J; Vegh AB; Martinez-Saguer I; Wuillemin WA; Edelman J; Williams-Herman D; Rojavin M; Rosenberg T
    Allergy Asthma Proc; 2017 May; 38(3):216-221. PubMed ID: 28441992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus.
    Riedl M
    Clin Ther; 2012 Mar; 34(3):623-30. PubMed ID: 22386830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
    Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
    Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch to icatibant in a patient affected by hereditary angioedema with high disease activity: a case report.
    Firinu D; Barca MP; Serusi L; Lorrai MM; Peralta MM; Manconi PE; Del Giacco SR
    Int J Immunopathol Pharmacol; 2012; 25(1):269-73. PubMed ID: 22507340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.